Altre lingue Eloxx Pharmaceuticals, Inc.

Azioni

ELOX

US29014R2022

Mercato chiuso - OTC Markets Altri mercati azionari 19:44:21 05/07/2024			Variaz. 5gg	Var. 1 gen.
0,75 ^USD	+7,43%		+8,70%	-37,50%

13/03	Almirall ed Eloxx Pharmaceuticals stipulano un accordo esclusivo per la licenza di ZKN-013 per le malattie dermatologiche rare	CI
13/03	Almirall firma un accordo di licenza con Eloxx Pharmaceuticals per il trattamento delle malattie della pelle	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	16/04
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	13/03
Eloxx Pharmaceuticals : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	13/03
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	13/03
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement	09/01
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board	28/12
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	15/12
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	13/11
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index	18/10/23
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index	13/10/23
Eloxx Pharmaceuticals : October 2023 Investor Presentation	10/10/23
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction	10/10/23
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	09/10/23
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	19/09/23
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	18/09/23
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development	15/09/23
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013	07/09/23
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013	07/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Eloxx Pharmaceuticals, Inc.

Azioni

ELOX

US29014R2022

Altre lingue

Filtri